Hawk Ridge Capital Management LP Decreases Position in Twist Bioscience Corporation $TWST

Key Points

• Hawk Ridge Capital Management LP reduced its stake in Twist Bioscience Corporation by 44.8%, now holding approximately 0.26% of the company worth $6.23 million after selling 128,794 shares.
• Multiple institutional investors have adjusted their positions in Twist Bioscience, with Versant Capital Management Inc increasing its stake by 547.2% during Q1.
• The stock currently holds a Moderate Buy consensus rating among analysts, with a price target of $49.40 reflecting positive market sentiment despite a reported loss of $0.47 EPS last quarter.

Hawk Ridge Capital Management LP cut its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 44.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,706 shares of the company's stock after selling 128,794 shares during the period. Hawk Ridge Capital Management LP owned 0.26% of Twist Bioscience worth $6,231,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. EdgePoint Investment Group Inc. purchased a new stake in Twist Bioscience during the first quarter valued at approximately $43,705,000. Bosun Asset Management LLC raised its holdings in shares of Twist Bioscience by 53.2% in the first quarter. Bosun Asset Management LLC now owns 12,398 shares of the company's stock worth $487,000 after buying an additional 4,307 shares during the period. AQR Capital Management LLC raised its holdings in shares of Twist Bioscience by 65.2% in the first quarter. AQR Capital Management LLC now owns 265,649 shares of the company's stock worth $10,429,000 after buying an additional 104,875 shares during the period. Royal Bank of Canada raised its holdings in shares of Twist Bioscience by 11.8% in the first quarter. Royal Bank of Canada now owns 40,373 shares of the company's stock worth $1,585,000 after buying an additional 4,254 shares during the period. Finally, Graham Capital Management L.P. raised its holdings in shares of Twist Bioscience by 35.0% in the first quarter. Graham Capital Management L.P. now owns 23,535 shares of the company's stock worth $924,000 after buying an additional 6,107 shares during the period.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CFO Adam Laponis sold 2,449 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total transaction of $93,429.35. Following the sale, the chief financial officer owned 103,569 shares of the company's stock, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Emily M. Leproust sold 1,678 shares of the stock in a transaction on Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $60,005.28. Following the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This represents a 0.26% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,250 shares of company stock worth $193,852 in the last ninety days. Insiders own 3.01% of the company's stock.

Twist Bioscience Stock Up 1.9%

NASDAQ TWST traded up $0.49 during midday trading on Monday, hitting $26.25. 2,249,947 shares of the company traded hands, compared to its average volume of 1,200,300. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The company has a market cap of $1.58 billion, a PE ratio of -18.10 and a beta of 2.31. The company's 50-day simple moving average is $31.74 and its 200-day simple moving average is $34.72. Twist Bioscience Corporation has a 52 week low of $24.28 and a 52 week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. The business had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analyst Ratings Changes

TWST has been the topic of several recent analyst reports. Evercore ISI set a $46.00 price target on Twist Bioscience in a report on Monday, August 4th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.